Dermatomyositis without elevation of creatine kinase presented as bronchiolitis obliterans organizing pneumonia.
- Author:
Young Ho LEE
1
;
Seong Jae CHOI
;
Jong Dae JI
;
Jae Jeong SHIM
;
Kyung Hoj KANG
;
Hyun Deuk CHO
;
Han Kyeom KIM
;
Gwan Gyu SONG
Author Information
1. Division of Rheumatology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Dermatomyositis;
Bronchiolitis Obliterans Organizing Pneumonia
- MeSH:
Azathioprine/administration +ACY- dosage;
Biopsy, Needle;
Bronchiolitis Obliterans Organizing Pneumonia/pathology;
Bronchiolitis Obliterans Organizing Pneumonia/diagnosis+ACo-;
Case Report;
Creatine Kinase/blood+ACo-;
Dermatomyositis/pathology;
Dermatomyositis/enzymology;
Dermatomyositis/drug therapy;
Dermatomyositis/diagnosis+ACo-;
Diagnosis, Differential;
Female;
Follow-Up Studies;
Human;
Middle Age;
Prednisone/administration +ACY- dosage;
Tomography, X-Ray Computed
- From:The Korean Journal of Internal Medicine
2000;15(1):85-88
- CountryRepublic of Korea
- Language:English
-
Abstract:
A case of dermatomyositis presented as bronchiolitis obliterans organizing pneumonia has been rarely reported. We describe a 46-year-old female patient with dermatomyositis without elevation of creatine kinase presented as bronchiolitis obliterans organizing pneumonia. She was treated with prednisolone and azathioprine. Over a 2-year follow-up she has had no elevation of creatine kinase. The patient remains asymptomatic and has no medication for dermatomyositis and bronchiolitis obliterans organizing pneumonia two years after initial treatment. It has been suggested that the prognosis of dermatomyositis without creatine kinase elevation may be poor. Because the prognosis of bronchiolitis obliterans organizing pneumonia is generally believed to be good, we tentatively suggest that the normal value of creatine kinase in dermatomyositis does not always seem to herald a poor prognosis, an associated malignancy or severe interstitial lung disease.